Literature DB >> 24196959

Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.

Jiechuang Su1, Yongchuan Gu, Frederik B Pruijn, Jeff B Smaill, Adam V Patterson, Christopher P Guise, William R Wilson.   

Abstract

Hypoxia, a ubiquitous feature of tumors, can be exploited by hypoxia-activated prodrugs (HAP) that are substrates for one-electron reduction in the absence of oxygen. NADPH:cytochrome P450 oxidoreductase (POR) is considered one of the major enzymes responsible, based on studies using purified enzyme or forced overexpression in cell lines. To examine the role of POR in HAP activation at endogenous levels of expression, POR knock-outs were generated in HCT116 and SiHa cells by targeted mutation of exon 8 using zinc finger nucleases. Absolute quantitation by proteotypic peptide mass spectrometry of DNA sequence-confirmed multiallelic mutants demonstrated expression of proteins with residual one-electron reductase activity in some clones and identified two (Hko2 from HCT116 and S2ko1 from SiHa) that were functionally null by multiple criteria. Sensitivities of the clones to 11 HAP (six nitroaromatics, three benzotriazine N-oxides, and two quinones) were compared with wild-type and POR-overexpressing cells. All except the quinones were potentiated by POR overexpression. Knocking out POR had a marked effect on antiproliferative activity of the 5-nitroquinoline SN24349 in both genetic backgrounds after anoxic exposure but little or no effect on activity of most other HAP, including the clinical stage 2-nitroimidazole mustard TH-302, dinitrobenzamide mustard PR-104A, and benzotriazine N-oxide SN30000. Clonogenic cell killing and reductive metabolism of PR-104A and SN30000 under anoxia also showed little change in the POR knock-outs. Thus, although POR expression is a potential biomarker of sensitivity to some HAP, identification of other one-electron reductases responsible for HAP activation is needed for their rational clinical development.

Entities:  

Keywords:  Flavoproteins; Gene Knock-out; Hypoxia; Hypoxia-activated Prodrug; Mass Spectrometry (MS); Molecular Cell Biology; NADPH:Cytochrome P450 Oxidoreductase; Proteotypic Peptides; Reductase; Zinc Finger Nuclease

Mesh:

Substances:

Year:  2013        PMID: 24196959      PMCID: PMC3873569          DOI: 10.1074/jbc.M113.505222

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.

Authors:  M I Walton; C R Wolf; P Workman
Journal:  Biochem Pharmacol       Date:  1992-07-22       Impact factor: 5.858

2.  Preparation and characterization of FAD-dependent NADPH-cytochrome P-450 reductase.

Authors:  G P Kurzban; H W Strobel
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

3.  Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation.

Authors:  H Olteanu; R Banerjee
Journal:  J Biol Chem       Date:  2001-07-20       Impact factor: 5.157

4.  Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase.

Authors:  Anna L Shen; Kathleen A O'Leary; Charles B Kasper
Journal:  J Biol Chem       Date:  2001-12-12       Impact factor: 5.157

5.  The role of catalytic superoxide formation in the O2 inhibition of nitroreductase.

Authors:  R P Mason; J L Holtzman
Journal:  Biochem Biophys Res Commun       Date:  1975-12-15       Impact factor: 3.575

6.  Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells.

Authors:  R P Baumann; W F Hodnick; H A Seow; M F Belcourt; S Rockwell; D H Sherman; A C Sartorelli
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

7.  Metabolic and radiolytic reduction of 4-alkylamino-5-nitroquinoline bioreductive drugs. Relationship to hypoxia-selective cytotoxicity.

Authors:  B G Siim; G J Atwell; W R Wilson
Journal:  Biochem Pharmacol       Date:  1994-10-18       Impact factor: 5.858

8.  Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions.

Authors:  P R Hoban; M I Walton; C N Robson; J Godden; I J Stratford; P Workman; A L Harris; I D Hickson
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

9.  Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions.

Authors:  J M Silva; P J O'Brien
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

10.  Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs.

Authors:  B G Siim; G J Atwell; W R Wilson
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

View more
  8 in total

1.  Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.

Authors:  Cho Rong Hong; Sunali Y Mehta; H D Sarath Liyanage; Sarah P McManaway; Ho H Lee; Jagdish K Jaiswal; Gib Bogle; Moana Tercel; Frederik B Pruijn; William R Wilson; Kevin O Hicks
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-10       Impact factor: 3.333

2.  The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.

Authors:  Katarzyna J Nytko; Ivo Grgic; Sabine Bender; Janosch Ott; Matthias Guckenberger; Oliver Riesterer; Martin Pruschy
Journal:  Oncotarget       Date:  2017-04-04

3.  Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs.

Authors:  Dinghua Liang; Xing Wu; Brian B Hasinoff; David E Herbert; Geoffrey K Tranmer
Journal:  Molecules       Date:  2018-08-15       Impact factor: 4.411

4.  Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.

Authors:  Tamara Heintze; Kathrin Klein; Ute Hofmann; Ulrich M Zanger
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

5.  Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.

Authors:  Victoria Jackson-Patel; Emily Liu; Matthew R Bull; Amir Ashoorzadeh; Gib Bogle; Anna Wolfram; Kevin O Hicks; Jeff B Smaill; Adam V Patterson
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

Review 6.  Therapeutic targeting of the hypoxic tumour microenvironment.

Authors:  Dean C Singleton; Andrew Macann; William R Wilson
Journal:  Nat Rev Clin Oncol       Date:  2021-07-29       Impact factor: 66.675

7.  Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.

Authors:  Cho R Hong; Gib Bogle; Jingli Wang; Kashyap Patel; Frederik B Pruijn; William R Wilson; Kevin O Hicks
Journal:  Front Pharmacol       Date:  2018-09-18       Impact factor: 5.810

8.  Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.

Authors:  Chris P Guise; Maria R Abbattista; Robert F Anderson; Dan Li; Rana Taghipouran; Angela Tsai; Su Jung Lee; Jeff B Smaill; William A Denny; Michael P Hay; William R Wilson; Kevin O Hicks; Adam V Patterson
Journal:  Molecules       Date:  2020-10-22       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.